A phase I trial of ZGN 1061 in patients with obesity

Trial Profile

A phase I trial of ZGN 1061 in patients with obesity

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs ZGN 1061 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; First in man
  • Sponsors Zafgen
  • Most Recent Events

    • 10 Jun 2017 Results published in a Zafgen media release.
    • 10 Jun 2017 According to a Zafgen media release, data from this trial was presented at the American Diabetes Association's 77th Annual Scientific Sessions (ADA).
    • 06 Jun 2017 Results will be presented at the American Diabetes Association 77th Scientific Sessions 2017, according to a Zafgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top